Geron Corporation Names Harout Semerjian as New CEO to Lead Commercialization of RYTELO

Geron Corporation (NASDAQ:GERN) is one of the most promising penny stocks under $5. On August 6, Geron Corporation announced the appointment of Harout Semerjian as its new President and Chief Executive Officer, effective the following day.

He succeeded Dawn Carter Bir, who has served as Interim President and CEO since March 2025. Bir will remain on the Board of Directors. Semerjian brings over 30 years of commercial hematology and oncology experience to Geron. His career includes leadership roles at Novartis, where he spent 17 years and served as global lead for Gleevec and KISQALI and head of the US hematology franchise.

This appointment comes at a crucial time for Geron, as the company is focused on expanding access to its recently approved product, RYTELO (imetelstat). RYTELO is approved in the US and the European Union for treating certain adult patients with lower-risk myelodysplastic syndromes with transfusion-dependent anemia. The company is also advancing its pipeline, including the pivotal Phase 3 trial/IMpactMF for imetelstat in relapsed/refractory myelofibrosis.

Geron Corporation (NASDAQ:GERN) is a commercial-stage biopharmaceutical company that focuses on the development of therapeutic products for oncology.

While we acknowledge the potential of GERN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.